Imunon Reports Q3 2026 Financial Results and Clinical Trial Updates
Imunon, Inc. (IMNN) reported its third-quarter 2026 financial results, highlighting a net loss of $3.8 million ($0.64 per share). While research and development expenses saw a slight decrease to $1.8 million due to lower manufacturing costs, the company faces significant liquidity challenges. Management noted that completing the pivotal Phase III OVATION-3 clinical trial will require additional capital, and auditors have included a going concern warning in their financial reports. On the clinical front, the company reported positive data from its OVATION-2 study, showing a 14.7-month increase in median survival for patients treated with IMNN-001 compared to the control group. The OVATION-3 trial is progressing with enrollment productivity exceeding internal assumptions. Additionally, the sale of the ThermoDox asset provides potential milestone payments of up to $16.5 million and a 4.8% equity stake in partner VoxelDox.
Tickers: $IMNN
Topics: clinical trial update earnings report financial results net loss
Read the full article at Motley Fool
Part of the story Imunon Reports Q3 2026 Financial Results and Clinical Trial Updates (8 articles)